Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma

Review
  • 10 Downloads

Abstract

Pheochromocytomas and their extra-adrenal counterpart paragangliomas (PGLs; together called PPGLs), belong to the family of neural crest-derived tumors. Given the overexpression of a wide variety of specific targets in PPGLs, it seems that these tumors are optimally suited to be imaged by specific radiopharmaceuticals. Thus, theranostics approaches with somatostatin agonists and antagonists are rapidly evolving in the setting of these tumors and may be considered as the next step in the therapeutic arsenal of metastatic PPGLs.

Keywords

Positron emission tomography Gallium-68 DOTA-analogues 6-(18F)fluoro-L-3,4-dihydroxyphenylalanine Somatostatin Paragangliomas Neuroendocrine 

Notes

Acknowledgements

This research was supported, in part, by the Intramural Research Program of the NIH, Eunice Kennedy Shriver NICHD.

References

  1. Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, Beschmout E, Morange I, Fakhry N, Castinetti F, Sebag F, Barlier A, Loundou A, Guillet B, Pacak K, Taieb D (2015) Prospective comparison of Ga-DOTATATE and F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Molec Imaging 43:1248–1257Google Scholar
  2. Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, Hahn PF, Boland GW (2004) Pheochromocytoma: an imaging chameleon. Radiographics 24(Suppl 1):S87–S99CrossRefPubMedGoogle Scholar
  3. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP (2009) 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 94:3922–3930CrossRefPubMedGoogle Scholar
  4. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K (2012) False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer 19:83–93CrossRefPubMedPubMedCentralGoogle Scholar
  5. Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, Pacak K, Guillet B, Taieb D (2017) The evolving role of succinate in tumor metabolism: an 18F–FDG-based study. J Nucl Med 58:1749–1755Google Scholar
  6. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27:4162–4168CrossRefPubMedPubMedCentralGoogle Scholar
  7. Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Poppel T, Brandau W, Jentzen W, Antoch G, Forsting M, Bockisch A, Kuhl H (2012) Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab 97:3833–3834CrossRefPubMedGoogle Scholar
  8. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP (2002) Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology 222:507–512CrossRefPubMedGoogle Scholar
  9. Hofman MS, Hicks RJ (2015) Moving beyond “Lumpology”: PET/CT imaging of Pheochromocytoma and Paraganglioma. Clin Canc Res 21:3815–3817CrossRefGoogle Scholar
  10. Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516CrossRefPubMedGoogle Scholar
  11. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, Adams KT, Perera S, Pacak K (2008) Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49:1613–1619CrossRefPubMedPubMedCentralGoogle Scholar
  12. Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV, Izatt L, Lalloo F, Brennan P, Cook J, Morrison PJ, Canham N, Armstrong R, Brewer C, Tomkins S, Donaldson A, Barwell J, Cole TR, Atkinson AB, Aylwin S, Ball SG, Srirangalingam U, Chew SL, Evans DG, Hodgson SV, Irving R, Woodward E, Macdonald F, Maher ER (2013) Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol 78:898–906CrossRefGoogle Scholar
  13. Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, Taieb D, Kebebew E, Lehnert H, Fojo AT, Pacak K (2015a) Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic Pheochromocytoma and Paraganglioma. Clin Canc Res 21:3888–3895CrossRefGoogle Scholar
  14. Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, Nambuba J, Herscovitch P, Sadowski SM, Fojo AT, Buchmann I, Kebebew E, Pacak K (2015b) 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared to other functional imaging modalities and CT/MRI. J Nucl Med 57:186–191Google Scholar
  15. Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, Lai EW, Pacak K (2007) The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 156:483–487CrossRefPubMedGoogle Scholar
  16. Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, Pattison DA, Gross DJ, Hicks RJ (2017) Efficacy of peptide receptor radionuclide therapy for functional metastatic Paraganglioma and Pheochromocytoma. J Clin Endocrinol Metab 102:3278–3287CrossRefPubMedGoogle Scholar
  17. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ (2013) A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Molec Imaging 40:1800–1808CrossRefGoogle Scholar
  18. Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, Gautsch K, Madleitner R, Nilica B, Sprinzl GM, Gastl G, Fraedrich G, Virgolini IJ (2015) (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging 42:33–41CrossRefPubMedGoogle Scholar
  19. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637–644PubMedGoogle Scholar
  20. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ (2001) State-of-the-art adrenal imaging. Radiographics 21:995–1012CrossRefPubMedGoogle Scholar
  21. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM (2000) Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 30:648–652CrossRefGoogle Scholar
  22. Mitchell DG (1992) Chemical shift magnetic resonance imaging: applications in the abdomen and pelvis. Top Magn Reson Imaging 4:46–63PubMedGoogle Scholar
  23. Naji M, Al-Nahhas A (2012) (68)Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Molec Imaging 39(Suppl 1):61-67Google Scholar
  24. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, Tan T, Rubello D, Al-Nahhas A (2011) 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 13:769–775CrossRefPubMedGoogle Scholar
  25. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, Schiavi F, Falcioni M, Kwok P, Bauters C, Lampe K, Fischer M, Edelman E, Benn DE, Robinson BG, Wiegand S, Rasp G, Stuck BA, Hoffmann MM, Sullivan M, Sevilla MA, Weiss MM, Peczkowska M, Kubaszek A, Pigny P, Ward RL, Learoyd D, Croxson M, Zabolotny D, Yaremchuk S, Draf W, Muresan M, Lorenz RR, Knipping S, Strohm M, Dyckhoff G, Matthias C, Reisch N, Preuss SF, Esser D, Walter MA, Kaftan H, Stover T, Fottner C, Gorgulla H, Malekpour M, Zarandy MM, Schipper J, Brase C, Glien A, Kuhnemund M, Koscielny S, Schwerdtfeger P, Valimaki M, Szyfter W, Finckh U, Zerres K, Cascon A, Opocher G, Ridder GJ, Januszewicz A, Suarez C, Eng C (2009) Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res 69:3650–3656CrossRefPubMedGoogle Scholar
  26. Pandit-Taskar N, Zanzonico PB, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko SK, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S (2017) Biodistribution and dosimetry of (18)F-meta Fluorobenzyl guanidine (MFBG): a first-in-human PET-CT imaging study of patients with neuroendocrine malignancies. J Nucl Med 117.193169Google Scholar
  27. Papathomas TG, Gaal J, Corssmit EP, Oudijk L, Korpershoek E, Heimdal K, Bayley JP, Morreau H, van Dooren M, Papaspyrou K, Schreiner T, Hansen T, Andresen PA, Restuccia DF, van Kessel I, van Leenders GJ, Kros JM, Looijenga LH, Hofland LJ, Mann W, van Nederveen FH, Mete O, Asa SL, de Krijger RR, Dinjens WN (2014) Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 170:1–12CrossRefPubMedGoogle Scholar
  28. Park BK, Kim B, Ko K, Jeong SY, Kwon GY (2006) Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: pathological correlation. Eur Radiol 16:642–647CrossRefPubMedGoogle Scholar
  29. Park BK, Kim CK, Kwon GY, Kim JH (2007) Re-evaluation of pheochromocytomas on delayed contrast-enhanced CT: washout enhancement and other imaging features. Eur Radiol 17:2804–2809CrossRefPubMedGoogle Scholar
  30. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie G, Baudin E, Chompret A, Ellison JW, Briere JJ, Rustin P, Gimenez-Roqueplo AP, Eng C, Carney JA, Stratakis CA (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16:79–88CrossRefPubMedGoogle Scholar
  31. Platts JK, Drew PJ, Harvey JN (1995) Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians Lond 29:299–306PubMedGoogle Scholar
  32. Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, Bal C (2015) Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine Neoplasia syndromes. Clin Nucl Med 40:e351–e356CrossRefPubMedGoogle Scholar
  33. Sharma P, Thakar A, Suman Kc S, Dhull VS, Singh H, Naswa N, Reddy RM, Karunanithi S, Kumar R, Malhotra A, Bal C (2013) 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck Paraganglioma. J Nucl Med 54:841–847CrossRefPubMedGoogle Scholar
  34. Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220:225–232CrossRefPubMedGoogle Scholar
  35. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, Investigators N-T (2017) Phase 3 trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376:125–135CrossRefPubMedGoogle Scholar
  36. Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 56:354–360PubMedGoogle Scholar
  37. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104:700–708CrossRefPubMedPubMedCentralGoogle Scholar
  38. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K (2009a) Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 94:4757–4767CrossRefPubMedPubMedCentralGoogle Scholar
  39. Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, Adams KT, Pacak K (2009b) Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol 71:11–17CrossRefGoogle Scholar
  40. Varghese JC, Hahn PF, Papanicolaou N, Mayo-Smith WW, Gaa JA, Lee MJ (1997) MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin Radiol 52:603–606CrossRefPubMedGoogle Scholar
  41. Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, Casagranda E, Severi S, Ambrosetti A, Schiavi F, Opocher G, Paganelli G (2012) Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res 44:411–414CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineLa Timone University Hospital, CERIMED, Aix-Marseille UniversityMarseilleFrance
  2. 2.Section on Medical NeuroendocrinologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesdaUSA

Personalised recommendations